By Jenny Nieto Nov. 16, 2018 On Nov. 16, CLSA was honored to convene a Meet & Greet with Representative-elect Mike Levin (D-San Juan Capistrano/San Diego) at our Washington, DC office. As you may know, attorney Mike Levin was elected Nov. 6 to serve as the new U.S. Representative for California’s 49th Congressional District. He … Continue reading CLSA Hosts Meet & Greet with Congressman-elect Mike Levin (CA-49)
CLSA’s federal government relations team is pleased to provide you with this update on the 2018 Midterm Elections, including the likely makeup of our incoming California delegation for the 116th Congress, and additional details on several key California congressional races you may be interested in.
Addressing drug pricing and improving healthcare access and affordability remains a salient topic on Capitol Hill, in the Trump Administration, with industry and the public. Over the summer, the Administration released its American Patients First blueprint, and over the past several weeks, the Administration has announced draft or final proposals intended to lower drug prices and increase access to affordable prescription drugs.
Both the House and Senate have adjourned until after the midterm elections. While the outcome of the elections will determine whether the Democrats win a majority in either the House or the Senate (or both), or if the Republicans maintain control of one or both chambers in the 116th Congress, both the House and Senate will return to Washington, D.C. in late November and early December (approximately 16-20 legislative days) to finish legislative work prior to the end of the year and the 115th Congress.
CLSA was a proud sponsor and participant of the 6th Annual Rally for Medical Research & National Day of Action on Sept. 13-14, 2018, an annual event that brings together more than 300 organizations to call on our nation’s policymakers to make funding for National Institutes of Health (NIH) a national priority.
On Sept. 11, CLSA co-hosted a multi-state life sciences association Congressional briefing on the patent system and how it works toward encouraging innovation in the development of life saving technologies.
CLSA’s federal government relations team provides an update on the outlook for key federal life sciences legislation likely to be addressed this year in Congress.
This August, CLSA participated in a medical technology industry roundtable discussion with Congressman Khanna (D-Fremont). Organized by AdvaMed and hosted by BD Biosciences in San Jose, attendees included representatives from CLSA members BD and Roche, and other medtech innovators including Boston Scientific, Elekta, Stryker and Varian.
In early August, CLSA organized a 2-day tour of multiple life sciences sector companies and research institutions across the Bay Area for Congressman Tony Cárdenas (D-San Fernando Valley), and his Washington DC-based staff. Cárdenas and our CLSA Federal Government Relations team visited & toured regional CLSA member companies including: Sutro Biopharma (San Carlos), 23andMe (Mountain View), Johnson & Johnson Innovation | JLABS (South San Francisco), and BioMarin (San Rafael and Novato).
Today, CLSA applauded the U.S. House passage of H.R. 184, the Protect Medical Innovation Act, which permanently repeals the job and innovation hindering 2.3% medical device excise tax levied on medical technology companies.